IP Library Granted Patent US 9,650,607
Granted Patent B2
US 9,650,607 · App. 13/858,376 · Granted May 16, 2017

Modalities for the treatment of degenerative diseases of the retina

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,650,607
App. No.
13/858,376
Granted
May 16, 2017
Kind
B2
Abstract

This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells.

Claims (13)

1. A method for treating a retinal disease or condition in a human subject comprising

transplanting, into the eye of the human subject, human RPE cells obtained by in vitro differentiation of human pluripotent cells that express Oct-4, alkaline phosphatase, SSEA-3, SSEA-4, TRA-I-60, and TRA-I-8I, wherein said RPE cells are disposed on a substrate or matrix, and have a normal karyotype, thereby treating the disease or condition as determined by functional testing.

2. The method of claim 1 , which comprises transplantation of the human RPE cells by vitrectomy surgery into the subretinal space of the eye of the human subject.

3. The method of claim 1 , wherein the method restores visual acuity in the subject.

4. The method of claim 1 , wherein visual acuity is restored to a moderate level.

5. The method of claim 1 , wherein the retinal disease or condition is a condition of retinal degeneration.

6. The method of claim 5 , wherein the condition of retinal degeneration comprises retinitis pigmentosa, RPE detachment, retinal dysplasia, retinal atrophy, retinopathy, or macular dystrophy.

7. The method of claim 5 , wherein the condition of retinal degeneration is macular degeneration.

8. The method of claim 7 , wherein said macular degeneration is age-related macular degeneration.

9. The method of claim 5 , wherein the condition of retinal degeneration is Stargardt disease.

10. The method of claim 5 , which comprises transplantation of the composition by vitrectomy surgery into the subretinal space of the eye of the human subject.

11. The method of claim 5 , wherein the method restores visual acuity in the subject.

12. The method of claim 5 , wherein visual acuity is restored to a moderate level.

Assignments (5)
CONFIRMATORY ASSIGNMENT Recorded Apr 5, 2024
From: ASTELLAS INSTITUTE FOR REGENERATIVE MEDICINE
To: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Reel/Frame 067024/0057 →
CHANGE OF NAME Recorded Jul 27, 2016
From: OCATA THERAPEUTICS, INC.
To: ASTELLAS INSTITUTE FOR REGENERATIVE MEDICINE
Reel/Frame 039493/0166 →
CHANGE OF NAME Recorded Jan 7, 2015
From: ADVANCED CELL TECHNOLOGY, INC.
To: OCATA THERAPEUTICS, INC.
Reel/Frame 034749/0622 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 23, 2014
From: KLIMANSKAYA, IRINA V.
To: ADVANCED CELL TECHNOLOGY, INC.
Reel/Frame 034023/0115 →
CONFIRMATORY ASSIGNMENT Recorded Oct 23, 2014
From: LANZA, ROBERT
To: ADVANCED CELL TECHNOLOGY, INC.
Reel/Frame 034038/0172 →